EXENATIDE SYNTHETIC
Clinical safety rating: safe
Animal studies have demonstrated safety
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
| Metabolism | Exenatide is primarily degraded by proteolytic degradation (neutral endopeptidase) and renal filtration, with minimal hepatic metabolism. |
| Excretion | Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces. |
| Half-life | Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing. |
| Protein binding | Approximately 25% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.2 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Subcutaneous: absolute bioavailability is approximately 65%. |
| Onset of Action | Subcutaneous: onset of glucose-lowering effect within 30 minutes. |
| Duration of Action | Duration of action is approximately 8-10 hours after a single subcutaneous dose, consistent with twice-daily dosing. |
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 30-50 mL/min: no adjustment; CrCl <30 mL/min: not recommended; ESRD on dialysis: contraindicated. |
| Liver impairment | No specific adjustment for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of renal impairment and hypoglycemia; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Drugs that are rapidly absorbed may be delayed (eg antibiotics) Can cause nausea and increased risk of thyroid C-cell tumors in rodents.
| Breastfeeding | It is unknown whether exenatide is excreted in human breast milk. Due to potential for adverse reactions in nursing infants, caution should be exercised. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with mother's clinical need for exenatide. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human exposure. No adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
No black box warning.
| Common Effects | Constipation Headache High blood pressure Nasal inflammation Urinary tract infection Fast heart rate Joint pain |
| Serious Effects |
["History of hypersensitivity to exenatide or any product components","Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)","End-stage renal disease (eGFR <15 mL/min/1.73 m²) or severe renal impairment (eGFR 15-29 mL/min/1.73 m²) if on dialysis","Severe gastrointestinal disease (e.g., gastroparesis)"]
| Precautions | ["Risk of acute pancreatitis; discontinue if suspected","Risk of hypoglycemia when used with insulin secretagogues or insulin","Renal impairment: increased risk of gastrointestinal adverse effects and acute renal failure; avoid in end-stage renal disease","Severe gastrointestinal disease: may exacerbate gastroparesis","Thyroid C-cell tumors: observed in rodent studies; monitor for serum calcitonin or thyroid masses","Immunogenicity: may develop anti-exenatide antibodies leading to loss of efficacy or injection site reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, weight, HbA1c. Assess for gastrointestinal adverse effects (nausea, vomiting) which may affect nutrition. Monitor fetal growth and well-being (ultrasound) as indicated for gestational diabetes or other high-risk conditions. |
| Fertility Effects | Animal studies: exenatide did not impair fertility at doses up to 130 times human exposure. Human data: no specific studies on fertility effects. GLP-1 receptor agonists may improve metabolic parameters that could affect fertility in patients with PCOS or obesity. |